f3781318-56be-4a43-b72d-a6bb65ef9a88
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- ANGIOGENESIS+0.450
- TGF_BETA_SIGNALING+0.430
- MYOGENESIS+0.410
- NOTCH_SIGNALING+0.410
- APICAL_JUNCTION+0.380
- HEDGEHOG_SIGNALING+0.370
- UV_RESPONSE_DN+0.370
- TNFA_SIGNALING_VIA_NFKB+0.340
- APICAL_SURFACE+0.320
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.490
- FATTY_ACID_METABOLISM-0.410
- BILE_ACID_METABOLISM-0.380
- PEROXISOME-0.380
- GLYCOLYSIS-0.310
- XENOBIOTIC_METABOLISM-0.290
- DNA_REPAIR-0.280
- ANDROGEN_RESPONSE-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- MTORC1_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3fcb923c-5dd2-4d6f-a6bb-8074ffb762be | — | — | 0.883 |
| 2 | 20020022.TNBC | — | D | 0.833 |
| 3 | 67be8235-7f6f-4c36-9ad7-c72f8308fb52 | — | — | 0.830 |
| 4 | SRR4296078 | — | cohortSQ1 | 0.827 |
| 5 | DRR168520 | — | — | 0.823 |
| 6 | SRR27320698 | — | — | 0.817 |
| 7 | TCGA-A2-A4RX-01A-11R-A266-07 | — | D | 0.812 |
| 8 | SRR8613770 | — | E | 0.800 |
| 9 | SRR10900585 | — | — | 0.794 |
| 10 | TCGA-56-8503-01A-11R-2403-07 | — | cohortSQ1 | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.430 | Inavolisib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |